| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Limaprost (formerly ONO1206; OP1206; ONO-1206; OP-1206) is, an alprostadil (prostaglandin E1) analogue, is a novel and potent vasodilator that increases blood flow and inhibits platelet aggregation. It is an orally bioavailable prostaglandin E1 analog with structural modifications intended to prolong half-life and improve potency. Limaprost reduces motor disturbances by increasing the production of insulin-like growth factor I in rats subjected to spinal cord injury.
| ln Vitro |
In human IVD cells, limaprost has an IC50 value of 70.9 nM and inhibits IL-1-mediated nerve growth factor (NGF) induction in a concentration-dependent manner [3].
|
|---|---|
| ln Vivo |
In rats, the vasopressin-induced ECG ST depression is alleviated when limaprost (OP1206) is administered orally at doses greater than 100 μg/kg [1]. Myocardial oxygen consumption, redox potential, heart rate, blood pressure, and myocardial blood flow are all unaffected by intracoronary injection of limaprost (OP1206; 1-100 ng/kg) in dogs [1]. Dogs' resistance in their big and small coronary arteries is decreased when limaprost (OP1206; 1-3 mg/kg) is injected intravenously [1]. When administered to guinea pigs at doses equivalent to or less than those that alleviate vasopressin-induced electrocardiographic ST depression, oral limaprost (OP1206) decreases platelet aggregation, adhesion, bleeding time, and thrombocytopenia caused by ADP and collagen infusion. Manifestations [1].
|
| References |
[1]. Tsuboi T, et al. Pharmacological evaluation of OP 1206, a prostaglandin E1 derivative, as an antianginal agent. Arch Int Pharmacodyn Ther. 1980 Sep;247(1):89-102.
[2]. Swainston Harrison T, et al. Limaprost. Drugs. 2007;67(1):109-18; discussion 119-20. [3]. Murata K, et al. PGE1 Attenuates IL-1β-induced NGF Expression in Human Intervertebral Disc Cells. Spine (Phila Pa 1976). 2016 Jun;41(12):E710-6. |
| Molecular Formula |
C22H36O5
|
|---|---|
| Molecular Weight |
380.51800
|
| CAS # |
74397-12-9
|
| Related CAS # |
Limaprost-d3;1263190-37-9
|
| SMILES |
O=C(O)/C=C/CCCC[C@H]1C(C[C@@H](O)[C@@H]1/C=C/[C@@H](O)C[C@@H](C)CCCC)=O
|
| InChi Key |
OJZYRQPMEIEQFC-UAWLTFRCSA-N
|
| InChi Code |
InChI=1S/C22H36O5/c1-3-4-9-16(2)14-17(23)12-13-19-18(20(24)15-21(19)25)10-7-5-6-8-11-22(26)27/h8,11-13,16-19,21,23,25H,3-7,9-10,14-15H2,1-2H3,(H,26,27)/b11-8+,13-12+/t16-,17+,18+,19+,21+/m0/s1
|
| Chemical Name |
(2E,11-alpha,13E,15S,17S)-11,15-Dihydroxy-17,20-dimethyl-9-oxoprosta-2,13-dien-1-oic acid
|
| Synonyms |
ONO 1206; OP1206; ONO 1206; ONO 1206; OP 1206; Limaprost; 17α,20-dimethyl-Δ2-Prostaglandin E1; 17α,20-dimethyl-δ2-PGE1; OP-1206
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 40 mg/mL (~105.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6280 mL | 13.1399 mL | 26.2798 mL | |
| 5 mM | 0.5256 mL | 2.6280 mL | 5.2560 mL | |
| 10 mM | 0.2628 mL | 1.3140 mL | 2.6280 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA